Clinique Medico Chirurgicale Charcot
- Address
- lock Available on a paid plan
Colorectal Cancer Research
At Clinique Medico Chirurgicale Charcot investigators are exploring new treatment combinations for microsatellite stable (MSS) metastatic colorectal cancer that exhibits a high immune infiltrate. The goal is to improve survival outcomes by pairing standard chemotherapy with targeted immunotherapy, while also assessing the impact of circulating tumor DNA on adjuvant decisions.
- Combination chemotherapy (XELOX or FOLFOX) with bevacizumab
- Integration of pembrolizumab as an immunotherapy partner
- Biomarker-driven patient selection based on immune profile
- Use of circulating tumor DNA to guide adjuvant therapy
These studies aim to set new standards for managing digestive system cancers and to expand therapeutic options for patients with advanced disease.
Breast Cancer Research
The oncology department focuses on a range of breast cancer subtypes, including early triple-negative breast cancer, luminal A disease in post‑menopausal women, and high‑risk HR‑positive/HER2‑negative tumors in premenopausal patients. Research seeks to personalize therapy by reducing hormone treatment duration, evaluating pembrolizumab after strong neoadjuvant responses, and employing gene‑expression tools such as Prosigna® to guide chemotherapy decisions.
- Neoadjuvant chemo‑immunotherapy for triple‑negative disease
- Optimizing adjuvant aromatase inhibitor duration
- Gene‑expression profiling to decide on chemotherapy use
- Risk‑adapted strategies for young women with early breast cancer
By tailoring treatment intensity, the trials aim to maintain high cure rates while minimizing unnecessary side effects for women across different risk groups.
Molecular Diagnostics & Personalized Medicine
Across both digestive and breast oncology programs, the site is advancing the use of molecular markers. Trials incorporate circulating tumor DNA monitoring and gene expression (Prosigna®)-driven algorithms to personalize adjuvant therapy, striving for better disease‑free survival and more precise treatment allocation.
- ctDNA‑based decision making for adjuvant chemotherapy
- Implementation of Prosigna® assay in routine care
- Integration of molecular biomarkers into trial design
- Development of tailored therapeutic approaches across tumor types
These initiatives reflect a commitment to cutting‑edge diagnostics that can refine therapy choices for patients with cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinique Medico Chirurgicale Charcot
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Adjuvant Pembrolizumab Versus Observation in Early Triple-Negative Breast Cancer with Pathologic Complete Response Post-Neoadjuvant Therapy | Unicancer | Phase III | Recruiting | Jul 2025 | — |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 3 | Unknown | 2024-03-26 | 2024-08-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.